share_log
Moomoo 24/7 ·  Jan 8 07:30
Marker Therapeutics Says 'Strategic Prioritization of Clinical Programs With Focus on MT-601 in Patients With Lymphoma'
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment